1185019-82-2

Basic information

• Product Name: 1-(2-methoxy-4-nitrophenyl)-3-methyl-1H-1,2,4-triazole
• Synonyms: 1-(2-methoxy-4-nitrophenyl)-3-methyl-1H-1,2,4-triazole;1H-1,2,4-Triazole, 1-(2-methoxy-4-nitrophenyl)-3-methyl-
• CAS NO: 1185019-82-2
• Molecular Formula: C₁₀H₁₀N₄O₃
• Molecular Weight: 234.2114
• Mol File: 1185019-82-2.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 464.7±55.0 °C(Predicted)
• Appearance: /
• Density: 1.40±0.1 g/cm3(Predicted)
• PKA: 1.41±0.50(Predicted)
• CAS DataBase Reference: 1-(2-methoxy-4-nitrophenyl)-3-methyl-1H-1,2,4-triazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-methoxy-4-nitrophenyl)-3-methyl-1H-1,2,4-triazole(1185019-82-2)
• EPA Substance Registry System: 1-(2-methoxy-4-nitrophenyl)-3-methyl-1H-1,2,4-triazole(1185019-82-2)

Safety Data

• Hazardous Substances Data: 1185019-82-2(Hazardous Substances Data)

Usage

General Description

The chemical 1-(2-methoxy-4-nitrophenyl)-3-methyl-1H-1,2,4-triazole, also known as Metribuzin, is a selective herbicide that is used to control a wide variety of annual and perennial broad-leaved weeds and grasses in crops such as soybeans, potatoes, peas, and tomatoes. It works by inhibiting photosynthesis in target plants, leading to their eventual death. Metribuzin is a white crystalline solid with a molecular weight of 214.19 g/mol and a melting point of 125-130°C. It is commonly applied as a pre-emergence or post-emergence herbicide and has a relatively low toxicity to non-target organisms, making it an important tool for sustainable crop production. However, it is important to use this chemical with caution, as it can be harmful if ingested or inhaled, and may cause skin and eye irritation.

Upstream product

• 122-51-0 orthoformic acid triethyl ester 
• 97-52-9 2-methoxy-4-nitrophenylamine 
• 7170-01-6 3-methyl-1H-[1,2,4]triazole 
• 454-16-0 1-fluoro-2-methoxy-4-nitrobenzene 
• 7170-01-6 5-methyl-1H-1,2,4-triazole 
• 1009-36-5 2-chloro-5-nitroanisole 

Downstream Products

• 1185019-85-5 3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)aniline 
• 1263865-62-8 7-(4-fluorophenyl)-N²-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-N⁴-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diamine 
• 1255700-80-1 (R)-2-(8-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenylamino)-2-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-4(5H)-yl)ethanol 
• 1255700-90-3 N-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-4-methyl-2-(6-methylpyridin-2-yl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine 
• 1255700-83-4 (R)-N-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-4-methyl-2-phenyl-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine 

Relevant articles and documents

DNA-Model-Based Design and Execution of Some Fused Benzodiazepine Hybrid Payloads for Antibody-Drug Conjugate Modality

A new series with the tetrahydroisoquinoline-fused benzodiazepine (TBD) ring system combined with the surrogates of (1-methyl-1H-pyrrol-3-yl)benzene ( MPB ) payloads were designed and executed for conjugation with a monoclonal antibody for anticancer therapeutics. DNA models helped in rationally identifying modifications of the MPB binding component and guided structure-activity relationship generation. This hybrid series of payloads exhibited excellent in vitro activity when tested against a panel of various cancer cell lines. One of the payloads was appended with a lysosome-cleavable peptide linker and conjugated with an anti-mesothelin antibody via a site-specific conjugation method mediated by the enzyme bacterial transglutaminase (BTGase). Antibody-drug conjugate (ADC) 50 demonstrated good plasma stability and lysosomal cleavage. A single intravenous dose of ADC 50 (5 or 10 nmol/kg) showed robust efficacy in an N87 gastric cancer xenograft model.

Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481

A triazine hit identified from a screen of the BMS compound collection was optimized for potency, in vivo activity, and off-target profile to produce the bicyclic pyrimidine γ-secretase modulator BMS-932481. The compound showed robust reductions of Aβsub

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.